Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Canonical and noncanonical regulatory roles for JAK2 in the pathogenesis of rheumatoid arthritis‐associated interstitial lung disease and idiopathic pulmonary fibrosis
Wang, Shaohua , Liu, Mengfei , Zhang, Jie , Wang, Faping , Zhang, Chujie , Roden, Anja C. , Ryu, Jay H. , Matteson, Eric L. , Tschumperlin, Daniel J. , Vassallo, Robert , Roden, Anja, Vassallo, Robert , Ryu, Jay H , Li, Xiujuan , Warrington, Kenneth J. , Sun, Jie

Mayo Clinic

The FASEB Journal | May 6, 2022 | Volume: 36 | Issue: 6 | Pages: No page available

10.1096/fj.202101436r | PMID 35522243 Get It

Abstract Idiopathic pulmonary fibrosis (IPF) and rheumatoid arthritis‐associated interstitial lung disease (RA‐ILD) are two fibrotic interstitial lung diseases that share the usual interstitial pneumonia (UIP) injury pattern. Here, we report that RNA sequencing of lung biopsies from patients with RA‐ILD and IPF revealed shared and distinct disease‐causing pathways. Analysis of transcriptomic data identified a JAK2 related JAK/STAT signaling pathway gene signature that distinguishes RA‐UIP from idiopathic UIP. This was further confirmed by immunohistostaining, which identified JAK2 phosphorylation with two distinct forms of activation: a cytoplasmic form of JAK2 activation in most IPF cases (13/20) and a nuclear form of p‐JAK2 in RA‐UIP (5/5) and a minority of IPF (6/20) cases. Further immunohistostaining identified STAT5A&B as the downstream transcriptional activator for JAK2‐mediated canonical signal transduction and phosphorylation of Tyr41 on histone H3 (H3Y41ph) as the downstream epigenetic regulation site for JAK2‐mediated noncanonical signal transduction. Gene Set Enrichment Analysis (GSEA) of the RNA‐Seq data further supported this shared pathogenic mechanism for the two diseases with the enrichment of STAT5A&B target gene sets as well as the JAK2 regulated H3Y41ph target gene set. This regulatory role of JAK2 in the pathogenesis of pulmonary fibrosis was further demonstrated by the attenuation of bleomycin‐induced murine pulmonary fibrosis using a JAK2‐selective pharmacological inhibitor CEP33779. In vitro studies with normal and IPF derived lung fibroblasts revealed a central role for JAK2 as an essential intermediary molecule in TGF‐β‐mediated myofibroblast trans‐differentiation, proliferation, and extracellular matrix protein production. These observations support a crucial role for JAK2 as an intermediary molecule in fibrotic lung disease development.
Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis
Li, Jing , Du, Heyue , Wang, Yang , Aertgeerts, Bert , Hao, Qiukui , Shen, Yanjiao , Li, Ling , Su, Na , Vandvik, Per Olav , Su, Baihai , Li, Sheyu , Hao, Qiukui , Li, Sheyu , Wang, Yang, Guyatt, Gordon , Delvaux, Nicolas , Bekkering, Geertruida Elsiena , Khan, Safi U. , Riaz, Irbaz Bin , Tian, Haoming

Mayo Clinic

Heart | May 4, 2022 | Volume: 108 | Issue: 16 | Pages: 1296-1302

10.1136/heartjnl-2021-320556 | PMID 35508401 Get It

Objective To determine the harms of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in people who need lipid-lowering therapy. Methods This systematic review included randomised controlled trials that compared PCSK9 inhibitors with placebo, standard care or active lipid-lowering comparators in people who need lipid-lowering therapy with the follow-up duration of at least 24 weeks. We summarised the relative effects for potential harms from PCSK9 inhibitors using random-effect pairwise meta-analyses and assessed the certainty of evidence using GRADE (Grading of Recommendation Assessment, Development and Evaluation) for each outcome. Results We included 32 trials with 65 861 participants (with the median follow-up duration of 40 weeks, ranging from 24 to 146 weeks). The meta-analysis showed an incidence of injection-site reaction leading to discontinuation (absolute incidence of 15 events (95% CI 11 to 20) per 1000 persons in a 5-year time frame, high certainty evidence). PCSK9 inhibitors do not increase the risk of new-onset diabetes mellitus, neurocognitive events, cataracts or gastrointestinal haemorrhage with high certainty evidence. PCSK9 inhibitors probably do not increase the risks of myalgia or muscular pain leading to discontinuation or any adverse events leading to discontinuation with moderate evidence certainty. Given very limited evidence, PCSK9 inhibitors might not increase influenza-like symptoms leading to discontinuation (risk ratio 1.5; 95% CI 0.06 to 36.58). We did not identify credible subgroup analyses results, including shorter versus longer follow-up duration of trials. Conclusions PCSK9 inhibitors slightly increase the risk of severe injection-site reaction but not cataracts, gastrointestinal haemorrhage, neurocognitive events, new-onset diabetes or severe myalgia or muscular pain.
B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS
Wang, Sophia , Vajdic, Claire M. , Linet, Martha S. , Slager, Susan L. , Nieters, Alexandra, Casabonne, Delphine , Cerhan, James R. , Cozen, Wendy , Brown, Elizabeth E. , Bracci, Paige M. , Turner, Jennifer , Hjalgrim, Henrik , Bhatti, Parveen , Flowers, Christopher R. , Paltiel, Ora , Holly, Elizabeth A., Weisenburger, Dennis D. , Cocco, Pierluigi , Breen, Elizabeth C. , Lan, Qing , Roos, Anneclaire J. De , Smith, Martyn T. , Kricker, Anne , Zheng, Tongzhang, Skibola, Christine F., Clavel, Jacqueline , Monnereau, Alain, Rothman, Nathaniel , Benavente, Yolanda , Hartge, Patricia, Smedby, Karin E. , Monnereau, Alain , Wang, Sophia S , Cerhan, James R , Cozen, Wendy , Martínez-Maza, Otoniel , Turner, Jennifer , Hjalgrim, Henrik , Bhatti, Parveen , Birmann, Brenda M , Kane, Eleanor , Weisenburger, Dennis D , Maynadié, Marc , Cocco, Pierluigi , Breen, Elizabeth Crabb , Lan, Qing , Brooks-Wilson, Angela R , Roman, Eve , Boffetta, Paolo , Kricker, Anne , Clavel, Jacqueline , Vajdic, Claire M , De Roos, Anneclaire J , Slager, Susan L , Voutsinas, Jenna M. , Alarcón, Graciela S. , Martı́nez-Maza, Otoniel , Zhang, Yawei , Birmann, Brenda M. , Kane, Eleanor , Foretová, Lenka , Brooks‐Wilson, Angela , Roman, Eve , Chanock, Stephen Jacob , Rothman, Nathaniel

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 4, 2022 | Volume: 31 | Issue: 5 | Pages: 1103-1110

10.1158/1055-9965.epi-21-0875 | PMID 35244686 Get It

Abstract Background: A previous International Lymphoma Epidemiology (InterLymph) Consortium evaluation of joint associations between five immune gene variants and autoimmune conditions reported interactions between B-cell response-mediated autoimmune conditions and the rs1800629 genotype on risk of B-cell non–Hodgkin lymphoma (NHL) subtypes. Here, we extend that evaluation using NHL subtype-specific polygenic risk scores (PRS) constructed from loci identified in genome-wide association studies of three common B-cell NHL subtypes. Methods: In a pooled analysis of NHL cases and controls of Caucasian descent from 14 participating InterLymph studies, we evaluated joint associations between B-cell–mediated autoimmune conditions and tertile (T) of PRS for risk of diffuse large B-cell lymphoma (DLBCL; n = 1,914), follicular lymphoma (n = 1,733), and marginal zone lymphoma (MZL; n = 407), using unconditional logistic regression. Results: We demonstrated a positive association of DLBCL PRS with DLBCL risk [T2 vs. T1: OR = 1.24; 95% confidence interval (CI), 1.08–1.43; T3 vs. T1: OR = 1.81; 95% CI, 1.59–2.07; P-trend (Ptrend) < 0.0001]. DLBCL risk also increased with increasing PRS tertile among those with an autoimmune condition, being highest for those with a B-cell–mediated autoimmune condition and a T3 PRS [OR = 6.46 vs. no autoimmune condition and a T1 PRS, Ptrend < 0.0001, P-interaction (Pinteraction) = 0.49]. Follicular lymphoma and MZL risk demonstrated no evidence of joint associations or significant Pinteraction. Conclusions: Our results suggest that PRS constructed from currently known subtype-specific loci may not necessarily capture biological pathways shared with autoimmune conditions. Impact: Targeted genetic (PRS) screening among population subsets with autoimmune conditions may offer opportunities for identifying those at highest risk for (and early detection from) DLBCL.
Differential mRNA expression in ileal and colonic biopsies in irritable bowel syndrome with diarrhea or constipation
Camilleri, Michael , Magnus, Yorick, Carlson, Paula, Chedid, Victor , Maselli, Daniel B. , Taylor, Ann, McKinzie, Sanna, Nagaraj, Nagaswaroop Kengunte , Busciglio, Irene, Nair, Asha, Kengunte Nagaraj, Nagaswaroop, Chedid, Victor G , Wang, Xiao‐Jing

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | May 3, 2022 | Volume: 323 | Issue: 2 | Pages: G88-G101

10.1152/ajpgi.00063.2022 | PMID 35502856 Get It

This study compares gene expression in mucosa of the terminal ileum, right colon, and left colon in patients with diarrhea- or constipation-predominant irritable bowel syndrome (IBS) and contrasts expression between these two disease entities and also between each entity and mucosa from healthy controls. The study shows there is differential expression of genes related to immune, transmitter, nociceptive, ion channel, and transporter functions, as well as reduced serine protease inhibition, in patients with IBS.
Effects of Microglia APOE Expression on Tau Pathology
Baker, Samantha K., Wang, Na , Bu, Guojun , Liu, Chia‐Chen

Mayo Clinic

The FASEB Journal | May 3, 2022 | Volume: 36 | Issue: S1 | Pages: No page available

10.1096/fasebj.2022.36.s1.r4949 Get It

Apolipoprotein E (APOE) is a lipid transporter involved in neural cholesterol metabolism. Highly expressed in astrocytes and microglia, APOE4, one of the three isoforms of the transporter, is a strong genetic risk factor for Alzheimer’s disease, while APOE3 is considered moderate risk and APOE2 protective. Despite recent advances in Alzheimer’s disease research, the exact mechanism by which APOE4 influences the progression of the disease has yet to be determined. One hallmark pathological feature of Alzheimer’s disease is the accumulation of hyperphosphorylated tau protein in the brain. To investigate the role of APOE isoform expression in the accumulation of hyperphosphorylated tau protein, a microglia‐specific cre‐ recombinase‐mediated APOE inducible mouse model was used. Phosphorylated‐tau accumulation, microglia activation, and neurodegeneration of the hippocampus and piriform cortex upon specific expression of APOE3 were quantified. APOE3 expressing mice had exacerbated neurodegeneration and tau accumulation in the hippocampus. Additionally, it appeared that APOE3 expressing mice had increased microglial activation. Thus, APOE expression may be involved in the activation of microglia in Alzheimer’s disease, eliciting an overactive immune response that accelerates disease progression.
Human Platelet Derived Exosome Product Attenuates Cigarette Smoke Induced Murine Emphysema
Wang, S., Xuan, W., Peterson, T., Stalboerger, P., Behfar, A., Vassallo, R., Wang, S., Vassallo, R.

Mayo Clinic

A17. COPD: SINGLE CELL RNA SEQUENCING, EPIGENETICS, MODELS, AND MACROPHAGES | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A1042-A1042

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1042 Get It

Diagnostic Accuracy of Interferon-Gamma Release Assays for Diagnosis of Smear-Negative Pulmonary Tuberculosis: A Systemic Review and Meta-Analysis
Lertjitbanjong, Ploypin , Eksombatchai, Dararat , Chesdachai, Supavit , Taweesedt, P.T., Pornchai, A., Wang, Z., Chesdachai, Supavit , Taweesedt, P.T., Thongprayoon, Charat , Petnak, Tananchai

Mayo Clinic

A59. TUBERCULOSIS | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A1917-A1917

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1917 Get It

A Novel Purified Exosome Product Ameliorates the Profibrotic Effects of TGF-β on Human Lung Fibroblasts In Vitro
Samhouri, B.F., Wang, F., Xuan, W., Wang, S., Peterson, Tim , Stalboerger, Paul G., Vassallo, R., Samhouri, B.F., Peterson, T., Behfar, Atta , Vassallo, R.

Mayo Clinic

A60. PULMONARY FIBROSIS: ANIMAL AND CELL CULTURE MODELS | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A1958-A1958

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1958 Get It

Targeting BCAT1 Combined with α-Ketoglutarate Triggers Metabolic Synthetic Lethality in Glioblastoma
Zhang, Bo , Peng, Hui , Zhou, Mi , Bao, Lei , Wang, Chenliang , Cai, Feng , Zhang, Hongxia , Wang, Jennifer E. , Niu, Yan-Ling, Chen, Yan , Hatanpaa, Kimmo J. , Copland, John A. , Wang, Yingfei , Luo, Weibo , Wang, Yijie , DeBerardinis, Ralph J.

Mayo Clinic

Cancer Research | May 2, 2022 | Volume: 82 | Issue: 13 | Pages: 2388-2402

10.1158/0008-5472.can-21-3868 | PMID 35499760 Get It

Abstract Branched-chain amino acid transaminase 1 (BCAT1) is upregulated selectively in human isocitrate dehydrogenase (IDH) wildtype (WT) but not mutant glioblastoma multiforme (GBM) and promotes IDHWT GBM growth. Through a metabolic synthetic lethal screen, we report here that α-ketoglutarate (AKG) kills IDHWT GBM cells when BCAT1 protein is lost, which is reversed by reexpression of BCAT1 or supplementation with branched-chain α-ketoacids (BCKA), downstream metabolic products of BCAT1. In patient-derived IDHWT GBM tumors in vitro and in vivo, cotreatment of BCAT1 inhibitor gabapentin and AKG resulted in synthetic lethality. However, AKG failed to evoke a synthetic lethal effect with loss of BCAT2, BCKDHA, or GPT2 in IDHWT GBM cells. Mechanistically, loss of BCAT1 increased the NAD+/NADH ratio but impaired oxidative phosphorylation, mTORC1 activity, and nucleotide biosynthesis. These metabolic alterations were synergistically augmented by AKG treatment, thereby causing mitochondrial dysfunction and depletion of cellular building blocks, including ATP, nucleotides, and proteins. Partial restoration of ATP, nucleotides, proteins, and mTORC1 activity by BCKA supplementation prevented IDHWT GBM cell death conferred by the combination of BCAT1 loss and AKG. These findings define a targetable metabolic vulnerability in the most common subset of GBM that is currently incurable. Significance: Metabolic synthetic lethal screening in IDHWT glioblastoma defines a vulnerability to ΑΚG following BCAT1 loss, uncovering a therapeutic strategy to improve glioblastoma treatment. See related commentary by Meurs and Nagrath, p. 2354
Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis
Qu, Wenchun , Engelberg-Cook, Erica , Yan, Dan , Siddik, Abu Bakar , Bu, Guojun , Allickson, Julie, Kubrova, Eva , Hare, Joshua M. , Pascual, Jorge M., Nayfeh, Tarek , Saadi, Samer , Durvasula, Ravindra, Richards, Elaine M. , Sanfilippo, Fred , Siddik, Abu Bakar , Allickson, Julie G, Hare, Joshua M , Kurtzberg, Joanne , Mallea, Jorge M. , Durvasula, Ravindra V, Bu, Guojun , Nayfeh, Tarek , Saadi, Samer , Wang, Zhen , Caplan, Arnold I. , Ricordi, Camillo , Pepine, Carl J. , Rodríguez, Ricardo López , March, Keith L.

Mayo Clinic

Stem Cells Translational Medicine | April 29, 2022 | Volume: 11 | Issue: 7 | Pages: 688-703

10.1093/stcltm/szac032 | PMID 35640138 Get It

Abstract MSC (a.k.a. mesenchymal stem cell or medicinal signaling cell) cell therapies show promise in decreasing mortality in acute respiratory distress syndrome (ARDS) and suggest benefits in treatment of COVID-19-related ARDS. We performed a meta-analysis of published trials assessing the efficacy and adverse events (AE) rates of MSC cell therapy in individuals hospitalized for COVID-19. Systematic searches were performed in multiple databases through November 3, 2021. Reports in all languages, including randomized clinical trials (RCTs), non-randomized interventional trials, and uncontrolled trials, were included. Random effects model was used to pool outcomes from RCTs and non-randomized interventional trials. Outcome measures included all-cause mortality, serious adverse events (SAEs), AEs, pulmonary function, laboratory, and imaging findings. A total of 736 patients were identified from 34 studies, which included 5 RCTs (n = 235), 7 non-randomized interventional trials (n = 370), and 22 uncontrolled comparative trials (n = 131). Patients aged on average 59.4 years and 32.2% were women. When compared with the control group, MSC cell therapy was associated with a reduction in all-cause mortality (RR = 0.54, 95% CI: 0.35-0.85, I 2 = 0.0%), reduction in SAEs (IRR = 0.36, 95% CI: 0.14-0.90, I 2 = 0.0%) and no significant difference in AE rate. A sub-group with pulmonary function studies suggested improvement in patients receiving MSC. These findings support the potential for MSC cell therapy to decrease all-cause mortality, reduce SAEs, and improve pulmonary function compared with conventional care. Large-scale double-blinded, well-powered RCTs should be conducted to further explore these results.